A Phase I Safety and Pharmacokinetic Study of Everolimus, an Oral mTOR Inhibitor, in Subjects With Impaired Hepatic Function

Authors
Peveling-Oberhag J.1 , Zeuzem S.1 , Yong W.P.2 , Kunz T.3 , Paquet T.4 , Bouillaud E.4 , Urva S.3 , Anak O.4 , Sellami D.3 , Kobalava Z. 5
Conference proceedings
EUROPEAN JOURNAL OF CANCER
Publisher
ELSEVIER SCI LTD
Language
English
Status
Published
DOI
10.1016/S0959-8049(11)71871-8
Volume
47
Year
2011
Organizations
  • 1 Klin JW Goethe Univ, Dept Med, Frankfurt 117548, Germany
  • 2 Natl Univ Singapore, Inst Canc, Singapore, Singapore
  • 3 Novartis Pharmaceut, NIA, Florham Pk, NJ USA
  • 4 Novartis Pharma AG, NIA, Basel, Switzerland
  • 5 Peoples Friendship Univ Russia, Ctr Appl Clin Pharmacol, Moscow, Russia
Date of creation
19.10.2018
Date of change
08.02.2022
Short link
https://repository.rudn.ru/en/records/article/record/8551/
Share

Other records